CLINICAL_TRIALS
trial_result
· 2015-04-24
Clinical Trial Update: Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women [Phase 3]
Summary
A Phase 3 trial in women with breast cancer compared fulvestrant 500 mg versus 250 mg; results were posted in 2015.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: AstraZeneca | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2015-04-24